RBC keeps Kos at outperform

Kos Pharmaceuticals Inc. was kept at an outperform, average risk, rating by RBC Capital Markets analyst Ken Trbovich. Merck's announcement that the New Drug Application for MK-0524B is delayed was expected news and further confirms time-to-market advantage for Kos' Simcor. However, Merck's plan to develop MK-0524A, a direct competitor to Kos' Niaspan, remains on track. Shares of the Cranbury, N.J.-based pharmaceutical company were up $2.44, or 5.19%, at $49.42. (Nasdaq: KOSP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.